Business Wire5h
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 …
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the EADV 2024 Congress ...
Ahammune Biosciences raises $5 million to fund novel vitiligo therapy
The funding will enable the company in conducting Phase II human clinical trials for its potential drug candidate for ...
entrackr12h
Biotech startup Ahammune Biosciences raises $5 Mn led by pi Ventures
Biotech startup Ahammune Biosciences has raised $5 million in Series A funding round led by pi Ventures. The round also ...
Biotech Startup Ahammune Biosciences Raises $5 Million in Series A Funding
Ahammune Biosciences, a clinical-stage therapeutics company focused on developing new treatments for skin diseases, has ...
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise ...
The Citizen15h
Albinism Society of South Africa fundraiser celebrates uniqueness
Celebrating the success of the Albinism Society of South Africa (ASSA) fundraising event held at Birchwood Hotel recently are ...
AbbVie: Upadacitinib Phase 3 Trials' Post-hoc Analysis Show Positive Results In Atopic Dermatitis
Drug maker AbbVie (ABBV) announced Wednesday positive results from a new post-hoc analysis of Phase 3 Studies, demonstrating efficacy ...
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
AbbVie (NYSE: ABBV) today announced positive results from a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. The analysis evaluated the efficacy of upadacitinib (15 mg or ...